Palivizumab en es it fr

Palivizumab Brand names, Palivizumab Analogs

Palivizumab Brand Names Mixture

  • No information avaliable

Palivizumab Chemical_Formula

No information avaliable

Palivizumab RX_link

http://www.rxlist.com/cgi/generic2/palivizumab.htm

Palivizumab fda sheet

Palivizumab msds (material safety sheet)

Palivizumab Synthesis Reference

sequence listed in Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997 Nov;176(5):1215-24.

Palivizumab Molecular Weight

No information avaliable

Palivizumab Melting Point

61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).

Palivizumab H2O Solubility

No information avaliable

Palivizumab State

Liquid

Palivizumab LogP

No information avaliable

Palivizumab Dosage Forms

Powder for solution

Palivizumab Indication

For treatment of respiratory diseases casued by respiratory syncytial virus

Palivizumab Pharmacology

Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.

Palivizumab Absorption

No information avaliable

Palivizumab side effects and Toxicity

No information avaliable

Palivizumab Patient Information

No information avaliable

Palivizumab Organisms Affected

No information avaliable